Country for PR: United Kingdom
Contributor: PR Newswire Europe
Friday, May 27 2022 - 00:34
Menarini inaugurates new regional headquarters in Dubai, UAE
DUBAI, UAE, May 26, 2022 /PRNewswire-AsiaNet/ --

The pharmaceutical group, present in 140 countries in the world, aims to raise 
standard of patient healthcare across the Middle East and Africa (MEA) region 
with innovative products and breakthrough research

Menarini, the leading Italian pharmaceutical group founded in 1886, today 
opened its regional headquarters in Dubai Science Park as part of its goal to 
expand its presence to the Middle East and Africa (MEA) region. Specializing in 
pharmaceutical research and production, consumer healthcare, oncology, and 
diagnostics, the Group is basing its new regional office, Menarini Middle East 
and Africa, in Dubai as it acts as an ideal hub location to elevate patient 
health and wellbeing in the region and to form pivotal connections with key 
industry stakeholders.

The inauguration drew the participation of influential healthcare dignitaries, 
most notably H.E. Dr. Amin Hussain Al Amiri, Assistant Undersecretary of Public 
Health Policy and Licensing at the UAE Ministry of Health and Prevention; H.E. 
Nicola Lener, Ambassador of Italy to the UAE, as well as high-level executives 
from Menarini's global team, as Dr Luca Lastrucci ,Group General Manager, Dr 
Ugur Bingol META President and Dr Basel Thaher Middle East Regional Head and 
MEA General Manager.

Elcin Barker Ergun, CEO Menarini Group and Member of the Board of Directors, 
said: "Today marks a historical moment for us as we open our regional offices 
in Dubai, a key inflection point, to significantly grow our presence and 
portfolio in the Middle East. As a 135 years old family owned company, we are 
looking forward to serve many more patients in the Middle East in the coming 
years with our unwavering commitment to Quality." 

Luca Lastrucci, Group General Manager at Menarini, commented: "Today's 
inauguration of our MEA headquarters in Dubai is a significant milestone for 
our company as we expand our investments in the MEA region. Our presence in a 
leading pharmaceutical hub like Dubai will strengthen Menarini's capabilities 
and improve market access in delivering breakthrough products in the areas of 
cardiovascular, gastrointestinal, and inflammatory diseases." Lastrucci added: 
"The UAE government has shown unwavering support for pharmaco-economic 
investments through its solid commercial infrastructure and impressive 
facilities. We see this as a vital step in the right direction for Menarini and 
will continue to work side-by-side with the UAE government to raise healthcare 
standards and support the wellbeing of communities across the UAE and 

Commenting on Menarini's new regional launch being perfectly aligned with the 
Dubai Industrial Strategy 2030, Dr. Ali Al Sayed, Director of Pharmaceutical 
Services Department at the Dubai Health Authority, said: "A defining objective 
of Dubai's 2030 strategy is to be a global hub for knowledge-based, sustainable 
and innovation focused businesses. As Menarini is a company with longstanding 
roots based in medical research, it will be a strong contributor to this 
visionary strategy.  Together, we share Dubai's overarching healthcare vision 
of positioning Dubai as the leading destination for healthcare knowledge, 
education and training."

Present in 140 countries with over 17,000 employees, the new Menarini regional 
headquarters in Dubai will be guided by Menarini's deeply rooted values of 
being patient-focused, people centered, and being committed to quality, 
integrity, and responsibility. This important milestone serves as a testament 
to Menarini's ongoing mission of curing diseases on a global scale and 
prioritizing patient health above all else.

About Menarini
The Menarini Group is a leading international pharmaceutical and diagnostics 
company, with a turnover of more than $4 billion and over 17,000 employees. 
Menarini is focused on therapeutic areas with high unmet needs with products 
for cardiology, oncology, pneumology, gastroenterology, infectious diseases, 
diabetology, inflammation and analgesia. With 18 production sites and 9 
Research and Development centers, Menarini's products are available in 140 
countries worldwide. For further information, please visit

Photo -
Photo -
Logo -

Source: Menarini Industrie Farmaceutiche Riunite